CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
December 2022—Bio-Rad Laboratories and NuProbe USA have entered into an agreement in which NuProbe will exclusively license its allele enrichment technologies to Bio-Rad for the development of multiplexed digital PCR assays.
“Bio-Rad provides the leading solution for digital PCR, and we are committed to providing oncology researchers with technologies that enable everything from biomarker discovery to clinical trials and patient monitoring of minimal residual disease,” Simon May, EVP and president of Life Sciences at Bio-Rad, said in a joint press release. “We look forward to working with NuProbe USA to develop the next generation of highly multiplexed digital PCR assays as part of our expanding oncology offering.”
Pages: 1 2